Sio Capital Management LLC lessened its holdings in Vaxart, Inc. (NASDAQ:VXRT - Free Report) by 7.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,608,244 shares of the biotechnology company's stock after selling 1,156,747 shares during the quarter. Vaxart accounts for approximately 4.6% of Sio Capital Management LLC's investment portfolio, making the stock its 5th biggest holding. Sio Capital Management LLC owned 7.67% of Vaxart worth $11,553,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Millennium Management LLC raised its stake in shares of Vaxart by 110.8% during the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company's stock worth $2,660,000 after purchasing an additional 2,095,274 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Vaxart by 19.9% in the 1st quarter. Vanguard Group Inc. now owns 8,449,362 shares of the biotechnology company's stock valued at $10,984,000 after acquiring an additional 1,404,391 shares during the period. Monaco Asset Management SAM acquired a new position in shares of Vaxart during the 2nd quarter worth about $402,000. Sequoia Financial Advisors LLC acquired a new stake in Vaxart in the 2nd quarter valued at about $65,000. Finally, Tidal Investments LLC bought a new position in Vaxart during the first quarter worth about $56,000. Institutional investors and hedge funds own 18.05% of the company's stock.
Vaxart Stock Performance
Shares of NASDAQ VXRT traded down $0.01 during trading hours on Friday, reaching $0.60. 586,308 shares of the stock were exchanged, compared to its average volume of 2,455,015. The stock's fifty day simple moving average is $0.75 and its 200 day simple moving average is $0.76. Vaxart, Inc. has a 52 week low of $0.52 and a 52 week high of $1.54. The firm has a market capitalization of $136.99 million, a price-to-earnings ratio of -1.49 and a beta of 0.70.
Wall Street Analyst Weigh In
Separately, Oppenheimer started coverage on Vaxart in a research note on Thursday, August 15th. They issued an "outperform" rating and a $4.00 price objective on the stock.
Check Out Our Latest Analysis on VXRT
About Vaxart
(
Free Report)
Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.
Featured Stories
Before you consider Vaxart, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.
While Vaxart currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
